The Cell and Gene Therapy Catapult (CGT Catapult) has announced a partnership agreement with UK-headquartered company TrakCel to incorporate its needle-to-needle supply chain management platform into the CGT Catapult’s large-scale cell and gene therapy manufacturing centre.
The 7200m2 manufacturing centre provides a state of the art GMP facility and support infrastructure to enable collaborators to carry out the large scale manufacture of cell and gene therapies as they progress towards commercial supply.
The partnership will allow CGT Catapult collaborators to benefit from an established software solution that is able to track cell therapies across the whole supply chain, integrated within its validated systems at the manufacturing centre and associated cryo-storage and logistics facilities.
The TrakCel technology will also link with Thermo Fisher Scientific’s new Fisher Bioservices CryoHub(SM), which is being built next to the manufacturing centre warehouse. The Cryohub will provide services for distribution of patient sample collection sets, cGMP cryo-storage of cell and gene therapies and also cryo-logistics for supply of these therapies throughout the UK and beyond.
Finally, the TrakCel technology will help further establish the Stevenage Bioscience Catalyst, where these services are located, as an emerging cell and gene therapy cluster not just for the UK but globally by offering a world first in life sciences innovation.
Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult, said: “This integration of GMP manufacturing, cryo-storage and logistics support within a complete end-to-end supply chain management solution is something which has not been done before and is critical to enabling commercial supply of cell and gene therapies in the UK.”